3 results

  • beleodaq

    (Belinostat)
    Acrotech Biopharma Inc
    Beleodaq is indicated for treating adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Approval is based on tumor response rates and duration, but improvement in survival or symptoms has not been established. Continued approval may depend on further clinical benefit verification.

  • folotyn

    (pralatrexate)
    Acrotech Biopharma Inc
    FOLOTYN is indicated for treating patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Its approval is based on overall response rates, with continued approval dependent on confirmation of clinical benefits in future trials.

  • zevalin

    (ibritumomab tiuxetan)
    Acrotech Biopharma Inc
    Zevalin is indicated for adult patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) and for those with previously untreated follicular NHL who have responded to first-line chemotherapy.